Product IntroductionBioactivity英文名:
Cardioxane描述: Cardioxane (ADR-529) 是一种心脏保护剂。
激酶实验: HTRF assay: Homogeneous time-resolved fluorescence (HTRF) assay measures the signal generated by 2 components when they are in close proximity. The p53–MDM2 binding assay uses a biotinylated peptide derived from the MDM2-binding domain of p53 and a truncated N-terminal portion of recombinant human GST-tagged MDM2 protein containing the p53-binding domain. Proteins for crystal structure studies are expressed in E. coli strain BL21 using the helper plasmid pUBS 520 coding for the lacIq repressor and the rare tRNAArg [AGA/AGG]. For crystallization, the frozen protein is thawed and concentrated to 9.8 mg/mL using a Centricon concentrator (3,000 MW cutoff). The complex is then formed by combining the protein with a slight molar excess of the inhibitor (stock solution is 100 mM in DMSO) and this solution is allowed to sit for 4 hours at 4°C. Cryopreserved crystals are used to collect diffraction data on beamline X8C at the National Synchrotron Light Source at Brookhaven National Laboratory.
体外活性: Dexrazoxane (10 mM), known clinically to limit anthracycline cardiac toxicity, prevents daunorubicin-induced myocyte apoptosis, but not necrosis induced by higher anthracycline concentrations in rat cardiac myocytes. [1] Dexrazoxane presumably exerts its cardioprotective effects by either binding free or loosely bound iron, or iron complexed to doxorubicin, thus preventing or reducing site-specific oxygen radical production that damages cellular components. [2] Dexrazoxane specifically abolishes the DNA damage signal gamma-H2AX induced by doxorubicin, but not camptothecin or hydrogen peroxide, in H9C2 cardiomyocytes. Dexrazoxane also induces rapid degradation of Top2beta, which paralleles the reduction of doxorubicin-induced DNA damage. Dexrazoxane antagonizes doxorubicin-induced DNA damage through its interference with Top2beta, which could implicate Top2beta in doxorubicin cardiotoxicity. [3] Dexrazoxane is hydrolyzed to its active form intracellularly and binds iron to prevent the formation of superhydroxide radicals, thus preventing mitochondrial destruction. [4]
体内活性: Dexrazoxane combined with doxorubicin, daunorubicin, or idarubicin reduces the tissue lesions in B6D2F1 mice (expressed as area under the curve of wound size times duration) by 96%, 70%, and 87%, respectively. Dexrazoxane combined with doxorubicin, daunorubicin, or idarubicin results in a statistically significant reduction in the fraction of mice with wounds as well as the duration of wounds. [5]
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: H2O : 55 mg/mL (180.5 mM)
DMSO : 56 mg/mL (183.8 mM)
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
关键字:
Dexrazoxane |
ICRF 187 |
inhibit |
Cardioxane Hydrochloride |
Inhibitor |
NSC-169780 |
Dexrazoxane hydrochloride |
ADR 529 |
ICRF187 |
ADR 529 Hydrochloride |
NSC 169780 |
ICRF 187 Hydrochloride |
NSC169780 |
ADR529 Hydrochloride |
Cardioxane |
ADR529 |
ICRF187 Hydrochloride |
ICRF-187 Hydrochloride相关产品:
Topixantrone 2HCl |
Lupalbigenin |
Amsacrine hydrochloride |
(4-NH2)-Exatecan |
Doxorubicin hydrochloride |
(±)-10-Hydroxycamptothecin |
Belotecan hydrochloride |
Ellagic acid |
α-Lapachone |
Bisantrene相关库:
Drug Repurposing Compound Library |
Approved Drug Library |
Clinical Compound Library |
Ferroptosis Compound Library |
Pediatric Drug Library |
DNA Damage & Repair Compound Library |
EMA Approved Drug Library |
Preclinical Compound Library |
NO PAINS Compound Library |
Bioactive Compound Library